Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer

doi:10.3748/wjg.v26.i6.598

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9175)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-2) series.

Item

Count

PDF

508

WORD

187

HTML

4595

Figures (1-7)

380

Tables (1-2)

229

Sum=5899

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

436

Download

664

Sum=1100

Publishing Process of This Article

Item

Count

Browse

832

Download

1344

Sum=2176

Feb 14, 2020 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (15)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Feb 14, 2020; 26(6): 598-613
Published online Feb 14, 2020. doi: 10.3748/wjg.v26.i6.598

Table 2 Regime-specific synergistic, additive or antagonistic effects of chemotherapeutic drugs and histone deacetylase inhibitors

Drugs	Treatment sequence and result of FA and median effect plot analysis		FA
Drugs			0.5	0.75	0.95
Cisplatin and VPA	Pre	Dose of Cis, VPA (µmol/L)	0.965, 386.359	2.711, 1084.65	15.361, 6144.61
	Pre	CI	0.352	0.471	0.784
	Concurrent	Dose of Cis, VPA (µmol/L)	0.705, 282.387	3.874, 1549.74	67.690, 27076.0
	Concurrent	CI	0.257	0.673	3.454
	Post	Dose of Cis, VPA (µmol/L)	3.254 ,1301.90	9.362, 3745.16	55.260, 22104.1
	Post	CI	1.188	1.627	2.820
Oxaliplatin and VPA	Pre	Dose of Oxa, VPA (µmol/L)	0.788, 394.469	2.094, 1047.04	10.796, 5398.39
	Pre	CI	0.404	0.453	0.552
	Concurrent	Dose of Oxa, VPA (µmol/L)	1.533, 766.633	4.305, 2152.92	24.406, 12203.2
	Concurrent	CI	0.786	0.933	1.249
	Post	Dose of Oxa, VPA (µmol/L)	2.362, 1181.47	8.451, 4225.64	71.917, 35958.6
	Post	CI	1.211	1.83182	3.68265
Epirubicin and TSA	Pre	Combined dose (µg)	0.030, 0.300	0.093, 0.931	0.623, 6.231
	Pre	CI	0.645	0.727	1.222
	Concurrent	Combined dose (µg)	0.129, 1.299	0.410, 4.105	2.835, 28.356
	Concurrent	CI	2.789	3.207	5.563
	Post	Combined dose (µg)	0.137, 1.375	0.301, 3.010	1.122, 11.220
	Post	CI	2.952	2.351	2.201

FA: Fraction affected; Pre: Pre-treatment; Post: Post-treatment; TSA: Trichostatin A; Cis: Cisplatin; VPA: Valproic acid; Oxa: Oxaliplatin; CI: Combination index. Dose at Fa-0.5 for VPA- 1827.79, TSA-1.50, Cisplatin-6.84, Oxaliplatin-4.18 and Epirubicin- 0.07; Dose at Fa-0.75 for VPA- 4165.97, TSA-2.61, Cisplatin-12.85, Oxaliplatin-10.33 and Epirubicin- 0.25; Dose at Fa 0.95 for VPA- 16628.5, TSA-6.56, Cisplatin-37.06, Oxaliplatin-47.30, and Epirubicin- 2.29.

Citation: Amnekar RV, Khan SA, Rashid M, Khade B, Thorat R, Gera P, Shrikhande SV, Smoot DT, Ashktorab H, Gupta S. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer. World J Gastroenterol 2020; 26(6): 598-613
URL: https://www.wjgnet.com/1007-9327/full/v26/i6/598.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i6.598